Phio Pharmaceuticals Corp
$ 1.08
1.89%
11 Jun - close price
- Market Cap 12,314,300 USD
- Current Price $ 1.08
- High / Low $ 1.08 / 1.05
- Stock P/E N/A
- Book Value 1.42
- EPS -1.38
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.47 %
- ROE -0.76 %
- 52 Week High 3.48
- 52 Week Low 0.81
About
Phio Pharmaceuticals Corp. The company is headquartered in Marlborough, Massachusetts.
Analyst Target Price
$14.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-05 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-14 | 2024-08-14 | 2024-04-01 | 2024-03-20 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.34 | -0.15 | -0.44 | -0.45 | -0.9379 | -0.85 | -1.54 | -3.62 | -0.85 | -0.85 | -1.14 | -1.4747 |
| Estimated EPS | -0.235 | -0.47 | -0.4 | -0.36 | None | -1.23 | -4.14 | -4.59 | -1.3 | -1.3 | -1.43 | None |
| Surprise | -0.105 | 0.32 | -0.04 | -0.09 | 0 | 0.38 | 2.6 | 0.97 | 0.45 | 0.45 | 0.29 | 0 |
| Surprise Percentage | -44.6809% | 68.0851% | -10% | -25% | None% | 30.8943% | 62.8019% | 21.1329% | 34.6154% | 34.6154% | 20.2797% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHIO
2026-06-10 20:40:23
This article focuses on the number of shareholders for Phio Pharmaceuticals Corp. (MUN:44R1). It provides a high-level overview within the TradingView platform, indicating market data, and references to financial information and community discussions. It emphasizes the availability of shareholder metrics over different periods.
2026-05-28 04:40:31
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) will participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series. CEO Robert Bitterman will present an overview of the company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for cutaneous carcinomas, followed by a live Q&A session. The presentation is scheduled for Thursday, May 28, 2026, at 12 PM EDT.
2026-05-26 11:45:36
Phio Pharmaceuticals Corp. announced its participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series. CEO Robert Bitterman will present an overview of the company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for cutaneous carcinomas, followed by a live Q&A session on Thursday, May 28, 2026, at 12 PM EDT. The company is clinical-stage and utilizes its proprietary gene silencing technology to eliminate cancer.
2026-05-26 10:39:36
Phio Pharmaceuticals will participate in Renmark Financial Communications' Live Virtual Non-Deal Roadshow Series on May 28, 2026, at 12 PM EDT. CEO Robert Bitterman will discuss the company's INTASYL siRNA gene silencing platform and its lead candidate PH-762 for cutaneous carcinomas, followed by a live Q&A. PH-762, which silences the PD-1 gene, is currently in a Phase 1b trial for various skin cancers as a potential non-surgical treatment.
2026-05-15 21:39:16
This article provides detailed stock information for Phio Pharmaceuticals Corp. (PHIO), including its current price, trading volume, price ranges, and shares outstanding. It also lists recent news and press releases related to the company's financial results, clinical study advancements, and participation in investor events, mainly focusing on its PH-762 and PH-894 drug development for skin cancer. The performance section indicates a negative trend across various periods.
2026-05-12 11:09:16
Phio Pharmaceuticals (NASDAQ: PHIO) announced an upcoming fireside chat on May 19, 2026, to discuss innovations in skin cancer treatment and prevention, focusing on their lead candidate, PH-762. The drug demonstrated a 65% pathological response rate in cutaneous squamous cell carcinoma (cSCC) during Phase 1b trials, with an 85% response in the highest-dose cohort and no dose-limiting toxicities. Phio also targets Q2 2026 for FDA engagement and projects its cash reserves will fund operations into the first half of 2027.
